Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Management of BRCA Mutated Ovarian Cancer

A new module by Jonathan Ledermann is now available. View the presentation and take the CME test today!

Learning objectives

  • To learn about the role of BRCA mutations and DNA repair defects in ovarian cancer
  • To provide an update on clinical activity and indications for use of PARP inhibitors in ovarian cancer
  • To learn about future strategies in the development of PARP inhibitors

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
Management of BRCA Mutated Ovarian Cancer 46 min. 54 slides - -

Germline mutations of BRCA1 or BRCA2 cancer susceptibility genes, are inherited as an autosomal dominant gene. The life time risk of ovarian cancer, taking BRCA 1 and 2 mutations together, is in the region of 40/60%. Although the mechanism of cancer development is not fully understood deletion of normal allele leads to cancer susceptibility through loss of function of homologous DNA repair, genomic stability, translational regulation, protein ubiquitination, chromatin remodelling and cell cycle control. A mutation is found in approximately 1 in 400 of the population but it is much higher in certain ethnic groups.

Epidemiological data estimate that a germline BRCA mutation is found in about 17% of women with high grade ovarian/fallopian tube/ peritoneal cancers. Counselling and testing pathways vary throughout Europe. Historically referrals were made to cancer geneticists and the focus has been on identifying unaffected relatives, and not for treatment decisions.

However, in this module, the author tries to convey a message that testing should no longer be dependent on family history and that new referral pathways are needed. Training of gynaecologists and oncologists in providing information and obtaining consent for germline BRCA testing is needed. Testing tumours for both somatic and germline mutations should be considered, as 6-8% of patients have somatic BRCA mutation.

This module outlines chapters on BRCA mutated ovarian cancer, epidemiology, PARP inhibitors in BRCA mutated ovarian cancer, clinical activity of PARP inhibitors in ovarian cancer, PARP inhibitors beyond BRCA mutated ovarian cancer, indications for use of PARP inhibitors in ovarian cancer, and future strategies for the development of PARP inhibitors.

In a part of the module on development strategies for PARP inhibitors in ovarian cancer, the author elaborates a comparison of PARP inhibitors with chemotherapy, questions if PARP inhibitors will have additive effects to chemotherapy, and provides evidence for maintenance therapy with PARP inhibitors.

The author further discusses PARP inhibitors for routine care of BRCA mutated ovarian cancer, side effects of PARP inhibitors, quality of life issues, landscape of PARP inhibitors in clinical development, patient selection for treatment with PARP inhibitors, and future directions.

Last update: 12 Aug 2015

The author has reported to be: Chief Investigator for Study 19 Olaparib; Co-Chief Investigator ARIEL 3 Rucaparib Trial. He has participated in the Advisory Boards of AstraZeneca and Clovis, without personal remuneration.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings